The FDA's Cardiovascular and Renal Drugs Advisory Committee on Wednesday voted 9-3 in favor of Alnylam Pharmaceuticals' Onpattro (patisiran) on whether its benefits outweigh its risks for the treatment of ATTR cardiomyopathy. Panelists agreed that the magnitu…